Eli Lilly & Co.
Eli Lilly and Company (LLY)
Overview
Eli Lilly and Company is a global pharmaceutical giant headquartered in Indianapolis, Indiana, that discovers, develops, manufactures, and markets human medicines, distributing products to roughly 125 countries. Founded in 1876 by Eli Lilly, a pharmaceutical chemist and Civil War veteran, the company has grown into the world's most valuable pharmaceutical company and, as of late 2025, the first healthcare company to reach a $1 trillion market capitalization. For fiscal 2025, Lilly reported roughly $65.2 billion in revenue (trailing-twelve-month revenue near $79.7 billion, reflecting explosive recent growth), net income of about $20.6 billion, and employs approximately 50,000 people worldwide.
What They Do & How They Make Money
Lilly's business model is classic large-molecule and small-molecule pharmaceutical research, development, and commercialization: it invests heavily in R&D and licensing/acquisition deals to discover new drugs, runs them through clinical trials and regulatory approval, then manufactures and markets approved medicines to generate revenue, largely protected by patent exclusivity for a fixed window before generic or biosimilar competition erodes pricing power. Historically diversified across diabetes care, oncology, immunology, and neuroscience, Lilly's growth has become heavily concentrated in a single blockbuster molecule — tirzepatide, sold as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management/obesity) — which together account for well over 60% of trailing revenue and have driven the company's valuation to record highs amid surging global demand for GLP-1/GIP-based obesity and diabetes treatments. Beyond tirzepatide, Lilly earns significant revenue from established diabetes therapies (Trulicity, Jardiance, insulin products Humalog, Humulin, and Basaglar), oncology drugs (led by Verzenio/abemaciclib), immunology treatments (led by Taltz/ixekizumab), and a growing neuroscience pipeline including Kisunla (donanemab) for Alzheimer's disease. The company also pursues bolt-on and platform acquisitions (e.g., Loxo Oncology for $8 billion in 2019, Armo Biosciences for $1.6 billion in 2018) to expand its pipeline and therapeutic reach.
Business Segments
Lilly does not report classic operating-division segments; instead it discloses revenue primarily by product/therapeutic area, reflecting how concentrated its growth has become:
- Diabetes & Obesity Care — by far the largest and fastest-growing category, anchored by tirzepatide (Mounjaro for diabetes, roughly 41% of trailing revenue, and Zepbound for obesity, roughly 21%), plus legacy diabetes drugs Trulicity (~5%), Jardiance (~5%), and insulin products Humalog, Humulin, and Basaglar (combined several percent). Together, diabetes/obesity products make up close to three-quarters of company revenue.
- Oncology — led by Verzenio (abemaciclib) for breast cancer, contributing roughly 12% of trailing revenue, alongside other cancer therapies built in part through the Loxo Oncology acquisition.
- Immunology — led by Taltz (ixekizumab) for psoriasis and related autoimmune conditions, contributing roughly 7% of trailing revenue.
- Neuroscience — a smaller but strategically important category including legacy products (historically Prozac, Cymbalta, Zyprexa, now largely genericized) and newer entrants like Kisunla (donanemab), an anti-amyloid antibody for early Alzheimer's disease.
Geographically, the U.S. is Lilly's dominant market (roughly two-thirds of revenue), with Europe, China, and Japan making up smaller but meaningful international shares.
Competitors
Lilly's competitive landscape varies significantly by therapeutic area:
- Novo Nordisk — Lilly's chief rival in diabetes and obesity, with its own GLP-1 franchise (Ozempic, Wegovy, semaglutide) directly competing against tirzepatide for the fast-growing obesity/weight-management market — arguably the most closely watched rivalry in pharma today.
- Pfizer, Regeneron Pharmaceuticals, AbbVie, and Amgen — compete across oncology, immunology, and various specialty categories.
- Roche, Merck, and Bristol Myers Squibb — major oncology competitors.
- Biogen and other Alzheimer's-focused developers — compete in the emerging neurodegenerative disease treatment space alongside Lilly's Kisunla.
- Emerging competitors in the obesity space also include smaller biotechs and additional entrants (oral GLP-1 candidates, next-generation combination therapies) racing to capture share of a market projected to grow substantially over the coming decade.
Competitive Position
Lilly's dominant competitive advantage right now is its first-mover and efficacy edge in the tirzepatide (dual GIP/GLP-1) mechanism, which has shown best-in-class weight-loss and glycemic results in head-to-head trials, driving extraordinary demand that has repeatedly outstripped manufacturing capacity. The company has invested billions in expanding manufacturing capacity for injectable and (in development) oral incretin therapies to meet demand and defend its lead as Novo Nordisk and other rivals push competing and next-generation products. Beyond diabetes/obesity, Lilly maintains a diversified, well-established base in oncology, immunology, and neuroscience, giving it multiple growth vectors and reducing (though not eliminating) reliance on any single drug class. Its scale, deep R&D pipeline, and history of successful acquisitions (Loxo Oncology, Armo Biosciences) support continued innovation, while its balance sheet strength (aided by tirzepatide's outsized profitability) funds aggressive reinvestment in both pipeline expansion and manufacturing capacity.
Key risks include: extreme revenue concentration in tirzepatide, meaning any safety signal, competitive setback, or reimbursement/pricing pressure on Mounjaro/Zepbound would disproportionately affect overall results — the company already faces litigation related to alleged gastroparesis side effects; intensifying obesity-market competition from Novo Nordisk and a wave of new entrants (injectable and oral) that could compress pricing or erode share over time; patent-cliff risk on legacy products as exclusivity windows close and biosimilar/generic competition emerges; political and regulatory pressure on U.S. drug pricing (including scrutiny of insulin and GLP-1 list prices) and potential policy changes affecting reimbursement; historical legal/regulatory exposure (e.g., a $1.415 billion settlement in 2009 over Zyprexa marketing practices) illustrating ongoing compliance risk; and typical pharmaceutical R&D risk — most experimental compounds fail in clinical trials, and Lilly must continue converting pipeline investment into approved, commercially successful therapies to sustain growth once tirzepatide's growth curve matures.